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Abstract
Background: Microarray-based comparative genomic hybridization (aCGH) is a powerful diagnostic tool for the
detection of DNA copy number gains and losses associated with chromosome abnormalities, many of which are
below the resolution of conventional chromosome analysis. It has been presumed that whole-genome
oligonucleotide (oligo) arrays identify more clinically significant copy-number abnormalities than whole-genome
bacterial artificial chromosome (BAC) arrays, yet this has not been systematically studied in a clinical diagnostic
setting.
Results: To determine the difference in detection rate between similarly designed BAC and oligo arrays, we
developed whole-genome BAC and oligonucleotide microarrays and validated them in a side-by-side comparison
of 466 consecutive clinical specimens submitted to our laboratory for aCGH. Of the 466 cases studied, 67 (14.3%)
had a copy-number imbalance of potential clinical significance detectable by the whole-genome BAC array, and
73 (15.6%) had a copy-number imbalance of potential clinical significance detectable by the whole-genome oligo
array. However, because both platforms identified copy number variants of unclear clinical significance, we
designed a systematic method for the interpretation of copy number alterations and tested an additional 3,443
cases by BAC array and 3,096 cases by oligo array. Of those cases tested on the BAC array, 17.6% were found to
have a copy-number abnormality of potential clinical significance, whereas the detection rate increased to 22.5%
for the cases tested by oligo array. In addition, we validated the oligo array for detection of mosaicism and found
that it could routinely detect mosaicism at levels of 30% and greater.
Conclusions: Although BAC arrays have faster turnaround times, the increased detection rate of oligo arrays makes
them attractive for clinical cytogenetic testing.
Introduction
Molecular cytogenetic techniques such as array-based
comparative genomic hybridization (aCGH) have revolu-
tionized cytogenetic diagnostics and, in turn, the clinical
management of patients with developmental delays and
multiple congenital anomalies [1,2]. These rapid, high-
resolution, and highly accurate techniques have identi-
fied numerous previously unrecognized chromosomal
syndromes [3-8], refined critical regions for established
genetic defects [9], and broadened our view of the “nor-
mal” diploid genome [10]. In addition, aCGH has given
the clinician a greater appreciation of variability in the
clinical presentation of many well-described conditions
[11,12] and allowed for the discovery of new conditions
with relatively mild phenotypes [13,14]. Furthermore,
the application of aCGH has created a paradigm shift in
genetics that has moved the description and discovery
of genetic conditions from the “phenotype-first”
approach, in which patients exhibiting similar clinical
features are identified prior to the discovery of an
underlying etiology, to a “genotype-first” approach, in
which a collection of individuals with similar copy-num-
ber imbalances can be examined for common clinical
features [15].
Originally, targeted microarrays constructed from bac-
terial artificial chromosomes (BAC) were developed for
the clinical laboratory because of their ability to clearly * Correspondence: ballif@signaturegenomics.com
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human genome known to play a role in genetic disease
[16]. This “less is more” idea prevailed in the early years
of clinical aCGH because the technology was new and
proof of principle was required before it could be
adopted for more widespread diagnostic use. Further-
more, the identification of copy number alterations of
unclear clinical significance was considered undesirable
to the diagnostician, the ordering physician, and the
patient’s family. Recently, the coverage of microarrays
has expanded to include more comprehensive coverage
of the human genome, leading many to suggest that
whole-genome BAC or oligo arrays are the next step in
the continued improvement in the detection rate of
cytogenetic abnormalities.
It has been presumed that whole-genome oligonucleo-
tide arrays, because they have higher resolutions, would
detect more copy number aberrations than whole-
genome BAC arrays. However, to our knowledge, there
has not been a systematic comparison of these two
whole-genome copy number screening technologies in a
clinical diagnostic environment. Therefore, to determine
which platform is most effective in identifying clinically
significant DNA copy number alterations, we designed a
w h o l e - g e n o m eB A Ca r r a ya n daw h o l e - g e n o m eo l i g o
array and compared the results in a blinded study of
466 clinical diagnostic specimens. In addition, we pro-
spectively evaluated 3,443 patients by the whole-genome
BAC array and 3,096 patients by the whole-genome
oligo array and compared the detection rates of clini-
cally significant abnormalities and those of unclear clini-
cal significance. Finally, we validated our oligo array
with 48 cases to determine the level of mosaicism that
can be reliably detected and compared that level to our
previously published cases analyzed using the BAC
array.
Materials and methods
Whole-genome BAC array design and aCGH
We constructed a whole-genome BAC array designed
for clinical diagnostic use using >4,600 BAC clones. All
clones were validated by FISH prior to inclusion on the
array using previously described validation procedures
[16]. Contigs of 3-6 overlapping clones were selected to
cover 1,543 genetic loci, including >150 known micro-
deletion/microduplication syndromes and increased den-
sity of coverage in the 5-10 Mb surrounding the
subtelomeric and pericentromeric regions of the gen-
ome. In addition, we placed contigs to cover >500 func-
tionally significant genes such as transcription factors
and other genes known to play important roles in devel-
opment. This coverage also includes genome-wide
representation with at least one contig in nearly every
chromosomal band at the resolution of an 850-band
karyotype. The mean gap size for the whole-genome
BAC array is ~1.6 Mb. Microarray manufacturing
and aCGH analysis using the whole-genome BAC array
were performed as previously described [13]. BAC arrays
were analyzed after a dye-swap, two-experiment analysis
[16], using sex-mismatched controls. Results were then
displayed using custom BAC aCGH analysis software
(Genoglyphix™; Signature Genomic Laboratories,
Spokane, WA).
Whole-genome Oligonucleotide Array Design and aCGH
Oligonucleotide-based microarray analysis was
performed using a custom-designed, 105K-feature
whole-genome microarray manufactured by Agilent
Technologies (Santa Clara, CA) with one probe every 10
kb in regions of interest–microdeletion/microduplication
syndromes, the pericentromeric regions, subtelomeres
and genes involved in important developmental path-
ways–for an average of 50 oligos per clinical locus. In
addition, to achieve backbone coverage, we placed a
probe, on average, every 35 kb throughout the rest of
the genome between the regions of interest. Genomic
DNA labeling was performed as described for BAC
arrays, whereas array hybridization and washing were
performed as specified by the manufacturer (Agilent
Technologies). A dye swap was not performed for the
oligo arrays, and sex-matched controls were used.
Arrays were scanned and analyzed as previously
described [17]. Results of aberration calls consisting of
five or more consecutive oligos were then displayed
using custom oligonucleotide aCGH analysis software
(Genoglyphix™; Signature Genomic Laboratories). The
use of five consecutive oligos achieved a resolution of
40 kb in the regions of interest and a resolution of 140
kb in the backbone.
Decision Algorithm for Clinically Significant Copy Number
Reporting
We developed a decision algorithm for classifying clini-
cally significant copy number alterations, alterations of
unclear clinical significance, and alterations of no cur-
rently known clinical significance. Alterations that were
associated with established chromosomal syndromes,
were large and affected a significant amount of gene
content, or were part of a complex rearrangement such
as an unbalanced translocation, insertion, or marker
chromosome were characterized as clinically significant.
Alterations with unclear clinical significance were most
commonly those which were not currently associated
with a syndrome but which affected gene content which
may have contributed to the patient’sp h e n o t y p ea n d
those which could not be precisely refined by the BAC
array. Alterations were considered to have no known
clinical significance if they were small, affected minimal
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common copy-number variation was known to occur in
the general population. Signature’so w nG e n o g l y p h i x
Chromosome Aberration Database (GCAD) was used as
a reference to assist in the interpretation of each altera-
tion. GCAD is a database of >11,000 chromosomal
abnormalities identified in >9,500 patients out of
>40,000 patients evaluated by our laboratory and con-
tains detailed statistics of each observed alteration
(breakpoint coordinates, size, gene content, etc.) as well
as clinical information pertaining to patient referral.
Fluorescence in situ Hybridization (FISH)
When possible, all copy number alterations detected by
microarray analysis were visualized by interphase and/or
metaphase FISH using a BAC probe located within the
region of gain or loss. FISH was performed as previously
described [18].
Patient Clinical Testing
To validate the custom-designed 105k oligo array com-
pared to the whole-genome BAC array, 466 cases were
run side-by-side in a platform comparison study. In
each case, the clinically validated BAC array results were
used for interpretation and reporting. Specimens with
known chromosome abnormalities, parental specimens,
and prenatal cases were excluded from the analysis.
In addition, we conducted a prospective study of 3,443
consecutive BAC microarray analyses and 3,096 conse-
cutive oligo microarray analyses in our clinical labora-
tory. The array platform used for testing in each case
was chosen by the referring physician at the time of
sample submission to our clinical diagnostic laboratory.
Cases with previously known chromosomal abnormal-
ities, parental samples, and prenatal specimens were
again excluded from the data collection.
Mosaicism Assessment
The ability of the oligo platform to detect mosaicism
was assessed on 48 patients previously known to carry
mosaic abnormalities at levels as low as 5%. The altera-
tions studied included a variety of interstitial, terminal,
and whole-chromosome copy-number abnormalities, as
well as marker chromosomes. The mosaic alteration in
each patient was initially assessed by BAC array and the
level of mosaicism determined by interphase FISH ana-
lysis when possible. In a separate experiment, mosaicism
was assessed using a dilution of cells from a male with
trisomy 21 with normal male control cells, as previously
described [19]. After FISH verification of the dilutions,
DNA was extracted from the diluted cells, labeled and
hybridized to the custom-designed oligo array as
described above.
Results
Platform comparison study
From the 466 cases analyzed by the BAC array, using
the previously described algorithm, we excluded 347
cases that only had aberrations located within regions
that contained no genes and/or aberrations that had
been established to be normal population variants by
Signature Genomic Laboratories or identified in the
Toronto Database of Genomic Variants (DGV, http://
projects.tcag.ca/variation/). After these cases were
excluded, 138 copy number alterations in 119 cases
(25.5% of the original 466 cases) remained that required
FISH analysis. These aberrations included subtelomeric
and pericentromeric gains for which FISH was required
to exclude an unbalanced translocation or a marker
chromosome. After FISH was performed, 60 aberrations
in 52 cases were classified as normal variants because
marker chromosomes and derivative chromosomes were
not identified and because these alterations were located
within regions where common copy number variation is
known to occur. Thus, alterations of potential clinical
significance according to our algorithm were identified
in 67 cases, a detection rate of 14.4%. Of these cases, 56
(12.0%) were considered to contain clinically significant
copy number alterations (Table 1), and 11 (2.4%) were
considered to contain copy number variants of unclear
clinical significance for which parental analyses were
recommended to further clarify the abnormality (Table
2). aCGH and FISH analysis performed on parental
samples revealed that six alterations of unclear signifi-
cance were inherited from a carrier parent and one was
a de novo event in the proband. The origin of the other
four unclear alterations could not be determined.
Using the oligo array, we identified 1,337 copy number
variations among the same 466 cases. Using the algo-
rithm previously described, we excluded 1,172 aberra-
tions that were located within regions that had no gene
content or those that were common copy number var-
iants. After these exclusions were made, 165 aberrations
in 138 cases (29.6%) remained that required FISH analy-
sis. After FISH analysis was performed, aberrations of
potential clinical significance were identified in 73 cases,
a detection rate of 15.7%. Of these, the same 56 (12.0%)
cases that were identified by the BAC platform were con-
sidered to contain clinically significant alterations (Table
1) and 17 (3.7%) were determined to contain copy num-
ber variants of unclear clinical significance.
Table 3 shows the six cases for which aberrations of
unclear clinical significance were identified by the oligo
array but not by the BAC array. In all six cases, the
aberrations either fell within the gaps in the BAC array
coverage or were only partially covered by one or more
BACs. The average size of the alterations that were not
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Pt. # Chr Band Start pos. End pos. Gain/Loss Size # of BACs # of Oligos
21637 chr16 p11.2 29,563,985 30,066,187 Loss 502,202 5 46
21992 chr16 p11.2 29,563,985 30,066,187 Loss 502,202 5 46
22013 chr16 p11.2 29,563,985 30,066,187 Loss 502,202 5 46
21993 chr10 q25.2q25.3 114,306,207 114,925,368 Loss 619,161 3 36
21756 chr2 q35 219,418,281 220,060,969 Loss 642,688 2 43
22002 chr2 q37.3 239,664,393 240,400,008 Loss 735,615 3 82
22334 chr10 q25.2q25.3 114,024,053 115,677,301 Gain 1,653,248 3 53
21688 chr16 p13.11p12.3 15,056,257 16,742,812 Gain 1,686,555 3 61
21667 chr17 p12 14,052,297 15,742,271 Gain 1,689,974 3 67
21896 chr4 q35.2 189,407,487 191,133,809 Loss 1,726,322 8 147
22269 chr2 q12.3q13 107,945,041 109,784,684 Loss 1,839,643 6 102
21640 chr19 q13.42 59,272,450 61,239,237 Gain 1,966,787 8 135
22117 chr9 q33.1 118,991,777 121,063,590 Gain 2,071,813 3 67
22066 chr8 p12p11.21 38,303,146 40,515,492 Gain 2,212,346 6 104
21786 chr1 q21.1 144,973,942 147,421,814 Gain 2,447,872 5 63
22237 chr1 q21.1 144,973,942 147,421,814 Gain 2,447,872 5 63
22310 chr22 q11.21 17,299,742 19,770,655 Loss 2,470,913 13 205
22050 chr22 q11.21 17,007,819 19,770,655 Loss 2,762,836 13 208
21936 chr1 q21.1 144,973,942 147,966,185 Gain 2,992,243 5 65
21719 chr2 q31.1 169,823,689 172,870,083 Loss 3,046,394 8 119
22128 chr4 q34.3 179,065,989 182,435,119 Loss 3,369,130 3 91
22006 chr17 p11.2 16,723,071 20,145,604 Loss 3,422,533 18 311
22174 chr1 q41q42.12 221,260,860 224,709,317 Loss 3,448,457 9 178
21971 chr22 q11.23q12.2 24,025,269 28,008,109 Loss 3,982,840 3 111
22073 chr15 q11.2q13.1 21,208,177 26,194,049 Loss 4,985,872 11 281
21687 chr16 q12.2q21 51,912,655 57,173,018 Loss 5,260,363 15 261
21975 chr5 p15.2p14.3 13,514,464 18,988,928 Loss 5,474,464 3 122
21555 chr7 p22.3p22.1 153,644 6,230,285 Gain 6,076,641 32 434
21547 chr2 q24.3q31.1 168,702,606 174,842,496 Loss 6,139,890 11 226
21755 chr11 p12p11.2 37,540,680 43,940,573 Loss 6,399,893 14 298
21761 chr3 p14.1p12.3 70,738,914 77,275,908 Loss 6,536,994 6 151
22151 chr15 q11.2q13.1 18,809,804 26,194,049 Gain 7,384,245 14 331
22322 chr8 p21.3p12 22,954,212 30,630,828 Loss 7,676,616 9 224
21889 chr2 q33.1q34 202,901,021 211,366,732 Gain 8,465,711 13 281
21723 chr5 q23.1q23.3 121,487,477 130,306,377 Loss 8,818,900 4 204
22337 chr1 p36.22p36.13 9,476,880 19,436,653 Loss 9,959,773 21 436
21795 chr1 p34.2p32.3 41,201,837 55,191,500 Gain 13,989,663 17 440
20986 chr12 p13.33p12.3 84,918 17,505,135 Gain 17,420,217 46 800
21957 chr11 q23.3q25 116,478,434 134,419,382 Gain 17,940,948 40 784
21596 chr1 q25.1q32.1 173,519,967 203,663,817 Gain 30,143,850 25 814
22055 chr3 p14.1p13 71,164,161 71,958,845 Loss 794,684 3 46
21566* chr17 p13.2p13.1 6,081,457 6,904,679 Loss 823,222 3 14
21558 chr22 q13.33 48,567,185 49,517,230 Loss 950,045 6 54
21770 chr8 p23.3 202,505 1,411,517 Loss 1,209,012 5 96
22254 chr8 p23.2 2,604,280 3,966,809 Loss 1,362,529 9 140
21937 chr7 q11.23 72,404,049 73,771,409 Loss 1,367,360 10 158
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1.42 Mb).
In two cases, the oligo microarray identified additional
complexity that was not recognized by the BAC array.
In patient 21566, the BAC array identified one intersti-
tial deletion of 17p13.2p13.1, whereas oligo array analy-
sis identified that deletion and an additional interstitial
deletion in the same band (data not shown). In patient
21897, the BAC array identified a 6.8 Mb terminal dele-
tion of 5p, whereas oligo array analysis identified that
deletion and a 1.4 Mb duplication proximal to the
deleted region (Figure 1).
Prospective Diagnostic Comparison
Of the 3,443 diagnostic specimens analyzed using our
whole-genome BAC array, 605 (17.6%) had copy num-
ber alterations. Using the previously described algo-
rithm, 365 (10.6%) had abnormalities that were classified
as clinically significant, whereas 240 (6.9%) had copy
number variants of unclear clinical significance.
Of the 3,096 diagnostic specimens analyzed using our
whole-genome oligo array during the same time period,
698 (22.5%) had copy number alterations. Using the
previously described algorithm, 477 (15.9%) of these
cases were determined to contain alterations considered
to be clinically significant and 221 (7.0%) were deter-
mined to contain copy number variants of unclear clini-
cal significance (Table 4).
The increased number of cases with clinically signifi-
cant alterations detected by the oligo array was found to
be statistically significant using a Fisher’s Exact Test
(OR = 1.5359, p < .0001). The increased number of
cases with alterations of unclear significance detected by
the oligo array was not statistically significant (OR =
1.0259, p = 0.8090).
Mosaicism Assessment
All but three of the 48 previously known mosaic altera-
tions were detected by the oligo array. FISH analysis
estimated that the proportion of uncultured cells carry-
ing the alteration was 24% in the first case, while the
proportion in cultured cells was 6%. In the second case,
5% of cells were found to carry the alteration by FISH
(data not shown). The proportion of cells carrying the
alteration in the third case could not be determined
because FISH confirmation was not possible on the
Table 2 Cases with Alterations of Unclear Significance Identified by BAC and Oligo aCGH
Pt. # Chr Band Start pos. End pos. Gain/Loss Size # of BACs # of Oligos Inheritance
22365 chr9 p23 9,881,385 9,984,838 Loss 103,453 2 15 Paternal
21702 chr16 p12.2 21,486,897 21,641,890 Loss 154,993 2 16 Paternal
21883 chr16 p12.1 21,974,396 22,338,234 Gain 363,838 3 49 Maternal
21860 chr16 p12.1 21,907,270 22,338,234 Loss 430,964 3 50 Unknown
22009 chr22 q11.21 19,069,125 19,770,655 Loss 701,530 4 70 Paternal
22102 chr16 p13.11 14,981,044 16,166,985 Gain 1,185,941 3 60 Maternal
22246 chr10 p11.22 31,591,310 32,792,762 Loss 1,201,452 2 40 Unknown
21893 chrX p11.32 45,930,652 46,382,140 Gain 451,488 3 34 Maternal
22273 chrX q28 153,355,101 154,317,591 Gain 962,490 5 46 Unknown
10245 chr3 p14.1 67,727,841 69,101,769 Loss 1,373,928 2 25 Unknown
22348 chr13 q22.2 74,989,699 75,378,640 Loss 388,941 3 51 De novo
Table 1: Cases with Alterations of Clinical Significance Identified by BAC and Oligo aCGH (Continued)
21710 chr15 q13.2q13.3 28,741,818 30,186,356 Loss 1,444,538 3 64
21722 chr15 q13.2q13.3 28,741,818 30,226,376 Loss 1,484,558 3 65
21739 chr15 q13.2q13.3 28,741,818 30,226,376 Loss 1,484,558 3 65
21787 chr15 q13.2q13.3 28,741,818 30,226,376 Loss 1,484,558 3 65
21897* chr5 p15.2 8,511,592 9,888,817 Gain 1,377,225 34 29
21884 chrX q28 152,676,750 153,059,428 Gain 382,678 3 44
21592 chrX p22.33q28 701 154,888,083 Gain 154,887,382 325 6888
22087 chrY p11.32 262,578 57,715,879 Gain 57,453,301 49 49
22285 chrX p21.1 31,759,551 31,830,811 Loss 71,260 2 11
22244 chr22 q13.33 49,342,961 49,514,486 Loss 171,525 2 56
*additional alterations identified by oligonucleotide aCGH.
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such as tetrasomy 12p, were successfully detected in
proportions of cells as low as 10% by the oligo array,
although this low threshold of detection was facilitated
by the tetrasomic nature of the rearrangement; the 4:2
ratio of patient to control DNA in this case was more
readily detected than the 3:2 ratio typically associated
with duplications. Figure 2 shows a 2.77 Mb interstitial
deletion at 16q12.1 present in 23% of cultured meta-
phase cells that was detected by the oligo array.
In the dilution series of trisomy 21 cells, shifts in the
aCGH data were distinguishable down to levels as low
as 10%, but could only be readily detected at a level of
30% or greater (Figure 3). As the proportion of trisomy
21 cells was increased from 10% to 30%, the average
log2 ratio of chromosome 21 increased from 0.08 to
0.21. During the prospective diagnostic comparison, 16
cases analyzed using the BAC array contained mosaic
alterations, whereas only 12 mosaic cases were identified
using the oligo array (Table 5). The increased number
of mosaic abnormalities detected by the BAC array was
determined to be not statistically significant (OR =
1.1999, p = 0.7066).
Discussion
BAC and oligo array platforms each have unique advan-
tages and disadvantages in a diagnostic setting; these
may include turnaround times, genomic coverage, and
Figure 1 Identification by oligonucleotide microarray of additional complexity missed by BAC microarray. (A) BAC microarray results
showing a single-copy loss of 34 BAC clones from the terminus of 5p, approximately 6.8 Mb in size (chr5: 387,034-7,150,950, based on UCSC
2006 hg 18 assembly). Probes are ordered on the x axis according to physical mapping positions, with the p-arm probes to the left and q-arm
probes to the right. (B) shows oligonucleotide microarray results of the terminal deletion shown in (A) in addition to single-copy gain of
29 probes from 5p, approximately 1.38 Mb in size (chr5: 8,511,592-9,888,817, based on UCSC 2006 hg 18 assembly). Probes are ordered as in the
BAC array. Regions shaded in blue represent deletions detected by microarray, whereas duplications are shaded in pink.
Table 3 Cases with Alterations of Unclear Significance Detected by Oligo Array but not Identified by BAC Array
Pt. # Chr Band Start pos. End pos. Gain/Loss Size # of Oligos
9756 chr2 p25.1 11,097,126 12,515,559 Loss 1,418,433 19
9886 chr1 q42.12 222,702,622 223,461,255 Loss 758,633 16
10141 chr2 q32.3q33.1 196,729,308 197,880,950 Loss 1,151,642 30
10114 chr15 q26.3 97,299,441 97,745,782 Gain 446,341 16
10292 chr7 p14.3 33,202,932 33,492,136 Loss 289,204 5
10019 chr2 p16.3 51,079,474 51,993,245 Gain 913,771 13
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platform is the detection rate of clinically significant
alterations. Our results demonstrate that our whole-
genome oligo array was able to detect such alterations
in 15.4% of patients tested, compared to the BAC array
detection rate of 10.6%, a statistically significant differ-
ence (Fisher’s Exact Test, p < 0.0001). The alterations
that constitute the 4.8% difference in detection rate
between the BAC and oligo arrays are either too small
to be detected by the BAC array but are not below the
resolution of the oligo platform (Figure 4) or fall within
g a p si nt h eB A Ca r r a yc o v e r a g e( F i g u r e5 ) .F i g u r e4
shows a 44 kb deletion of 17p13.3 detected in a patient
referred to our laboratory for convulsions. This deletion
encompasses the first exon of PAFAH1B1 (LIS1). While
it is not known whether this deletion results in a null
allele or simply a truncated gene product, hemizygous
deletions and mutations of this gene are found in
patients with isolated lissencephaly type 1 (OMIM
607432) and have been linked to epileptic seizures and
convulsions [20,21]. Although RP11-135N5 provides
coverage of this region on the BAC array, FISH analysis
using this clone could not confirm the deletion in any
cells because of the deletion’s small size compared to
the FISH probe used. Thus, this clinically significant
deletion could only have been reliably detected using
the oligo platform. Although oligo-based aCGH has the
power to detect alterations smaller than the size of a
BAC probe, BAC-based aCGH has an advantage in that
the analysis makes evident the appropriate probe to be
used for FISH confirmation. In addition, this probe is
usually readily available because of its inclusion on the
microarray platform and will have a high rate of suc-
cessful confirmation. When oligonucleotide-based
aCGH is performed, BAC probes must be specifically
selected for the FISH confirmation of each small
abnormality that is detected. Once a probe has been
selected, it must also be specially prepared or ordered
before FISH can be performed. This process increases
both the time it takes to perform FISH confirmation of
oligo aCGH results and the cost associated with the
analysis.
Figure 5 shows a 2.9 Mb deletion of 6q14.1 detected
in a patient referred to our laboratory for developmental
delay and dysmorphic features. This deletion encom-
passes eight genes: PHIP, HMGN3, LCA5, SH3BGRL2,
ELOVL4, TTK, BCKDHB, two of which are known to be
associated with human disease [22-24]. Although this
Table 4 Summary of the Prospective Diagnostic
Comparison
BAC Oligo
Total 3,443 3,096
Abnormal 605 (17.6%) 698 (22.5%)
Significant 365 (10.6%) 477 (15.4%)
Unclear 240 (7.0%) 221 (7.1%)
Mosaic 16 (0.5%) 12 (0.4%)
Figure 2 Oligonucleotide microarray analysis of a mosaic 16q12.1 deletion (shaded blue region). The zoomed-in microarray plot shows a
single-copy loss of 289 probes from 16q12.1, approximately 2.77 Mb in size (chr16: 46,837,260-49,605,054, based on UCSC 2006 hg 18 assembly).
Probes are ordered on the x axis according to physical mapping positions, with the most proximal 16q11.2 probes to the left and the most
distal 16q12.2 probes to the right.
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w i t h i nag a pi nt h ec o v e r a g eo fo u rB A Ca r r a ya n d
could only be detected using the oligo platform because
of its more uniform backbone coverage.
The detection rate of alterations of unclear clinical
significance is also a concern during the selection of a
microarray platform in a clinical diagnostic setting. Our
data suggest that both the oligo and BAC platforms
detect similar numbers of abnormalities of unclear sig-
nificance (7.0% by BAC and 7.1% by oligo), although the
circumstances leading to an unclear clinical interpreta-
tion may vary between the platforms. On the BAC plat-
form, unclear results are often associated with gaps in
coverage which prevent the precise determination of the
breakpoints and gene content of an abnormal region.
This lack of information prohibits definitive interpreta-
tion of the clinical significance of the alteration. Figure 6
presents a 262 kb deletion of 9q33.1 detected by BAC
array in a patient referred for developmental delay, dys-
morphic features, and multiple congenital anomalies.
The boundaries of this alteration as defined by BAC
array include only one gene, TLR4 [25]. However, gaps
in BAC coverage on both sides of the alteration span
4.5 Mb proximally and 4.0 Mb distally. As a result of
these coverage gaps, this alteration, though estimated to
be just 262 kb, may be as large as 8.7 Mb and include
up to 48 additional genes. The design of BAC arrays
with dense clone coverage is possible; however, probe
density is limited by the availability of BAC clones and
the presence of potentially interfering genomic architec-
ture such as segmental duplications. In addition, BAC-
based microarrays will not reliably detect abnormalities
smaller than the size of an individual probe–80-200 kb,
on average, for BAC clones.
Figure 3 Oligonucleotide microarray analysis of artificially derived mosaic trisomy 21 samples. (A) 10% trisomy 21 showing a very subtle
copy-number gain for all clones on chromosome 21. The profile was generated using DNA extracted from a mixture of blood which contained
10% WBCs from a trisomy 21 subject and 90% WBCs from a normal male individual. (B) 15% trisomy 21, generated as in (A), showing a very
subtle copy-number gain for all clones on chromosome 21. (C) 20% trisomy 21, generated as in (A) showing a subtle copy-number gain for all
clones on chromosome 21. (D) 30% trisomy 21, generated as in (A), showing a clear copy-number gain for all clones on chromosome 21. The
inset images to the right of each array plot show the average log2 ratio of all probes mapping to chromosome 21, with the horizontal dotted
line representing a log2 ratio of zero and the vertical dotted line representing the centromere. A pink bar plotted above the horizontal line
represents a copy-number gain of all probes on chromosome 21. To the left of each inset image is the average log2 ratio at the specified
proportion of trisomic cells.
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Page 8 of 14Although gaps in coverage and limited breakpoint-
resolving power are primarily a concern for BAC plat-
forms, both oligo and BAC platforms produce results
that are unclear because a lack of published evidence
prevents a conclusive association between the gene con-
tent of an alteration and the clinical features of the
patient from being made. Figure 7 presents a 160 kb
deletion of 4q25 detected by oligo array in a patient
referred for developmental delay. Follow-up analysis
performed on this patient’s parents revealed that this
alteration was de novo in origin. This alteration deletes
two genes, PAPSS1 and SGMS2. While mutations or
alterations of these genes have not been associated with
disease in humans, it has been shown that PAPSS1 plays
a key role in post-translational modification and SGMS2
mediates the production of sphingomyelin [26,27]. Thus,
although the gene content and inheritance pattern of
this deletion suggest a causative role in the patient’s
clinical features, a lack of published information linking
the genes affected by this alteration with a distinct phe-
notype prevents a clear interpretation from being made
based on only aCGH results. This type of unclear result,
although more prominent with oligo platforms (4.2% by
BAC vs. 7.1% by oligo), is an element of all aCGH ana-
lysis regardless of platform and accentuates the need for
databases containing aCGH results in combination with
phenotypic information. Although the number of char-
acterized genetic disorders and genomic regions is
rapidly increasing, the clinical consequences of altera-
tions involving much of the genome still remain unclear.
The increase in the number of copy number altera-
tions identified by higher-resolution whole-genome
arrays underscores the need for a variety of tools to
facilitate the interpretation of array results in a clinical
diagnostic setting. We propose the use of an algorithm
such as the one outlined here in conjunction with data-
bases of normal population variants, clinically significant
alterations, and those of unclear significance. Although
such databases can provide invaluable context for the
analysis of aCGH data, care must be taken by the diag-
nostician when comparing their data to pre-existing
databases of copy-number variations. For example, data
i nt h eD G Va r ep o o l e df r o mav a r i e t yo fs o u r c e s ,p l a t -
forms, and populations using a variety of different con-
trols and without independent verification, and thus
may not be appropriate for comparison in all situations.
Furthermore, recent evidence suggests that most data in
the DGV overestimate the size of the regions involved
because they are dependent primarily on BAC array
data, which has a tendency to overestimate the true size
of small aberrations [28]. Thus, the most useful CNV
databases may be those generated by individual labora-
tories using identical reference controls and array plat-
forms. Based on our experience, we have constructed a
database of abnormal copy number aberrations identi-
fied by BAC and oligo aCGH in our laboratory and a
database of copy-number variations thought to have no
significance. Such databases are essential for under-
standing the various copy number aberrations identified
by microarray analysis.
Genotype-phenotype correlations in a diagnostic set-
ting must address a variety of factors including gene con-
tent, potential position effects, aberration size, and
inheritance patterns. These factors often present conflict-
ing evidence about the potential clinical significance of a
rare alteration. For instance, the size of an abnormality is
Table 5 Mosaic Alterations Detected in the Prospective
Diagnostic Comparison
Pt. # Proportion
(%)
Classification
BAC
25885 10 45,X
25838 10 47,XX,i(12)(p10)
27745 10 46,XY,trp(12)(p13.33p10)
26912 18 47,XY,i(8)(p10)
26358 20 46,XX,dup(2)(p14p11.2)
26880 24 47,XX,+9
23302 27 47,XX,+der(9)(p21.2q11)
23919 46 47,XY,+der(12)(p13.33q11)
26127 53 46,XY,del(18)(q22.3q23)
26750 57 47,XY,+der(8)(p11.22q11)
26894 60 45,X
24887 70 46,XX,der(14)dup(14)(q32.13q32.2)del(14)
(q32.3q32.33)
23159 70 47,XYY
23155 77 46,XX,idic(18)(q21.33)
23215 87 47,XX,+21
25862 93 48,XX,+der(13)(pterq12.12),+der(20)(p11.21q11)
Oligo
27978 21 48,XY,+der(13)(pterq12.11),+der(?)(?::Xp22.31-
>Xp22.31::Xp22.2->Xp22.12::?->cen->?)
32047 27 47,XXY
32374 27 46,XX,r(X)(p11.1q21.1)
32875 33 47,XY,+inv dup(22)(q11.21)
29361 53 47,XX,+der(11)(p11.2q11)
31439 63 47,XY,+der(12)(:p13.33::p13.31->p13.2::p11.23::
p11.22->p11.21::?->12cen->?::p11.21->p11.22::
p11.23::p13.2->::p13.31::p13.33:)
31633 63 48,XX,+der(4)(p13q12),+der(13)(pterq12.11)
30028 77 46,XY,del(7)(q22.1q22.3),del(12)(q21.31q22)
31336 80 46,XX,idic(X)(q21.1)
27105 90 47,XX,+der(13)(pterq12.12)
29786 90 46,X,+der(X)(p11.21q11.1)
30218 93 47,XY,+der(17)(p11q11.2)
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Page 9 of 14Figure 4 Oligonucleotide microarray characterization of an interstitial deletion at 17p13.3. The zoomed-in microarray plot shows a single-
copy loss of six probes from the short arm of chromosome 17 at 17p13.3, approximately 44.0 kb in size (chr17: 2,415,074-2,459,051, based on
UCSC 2006 hg 18 assembly). Probes are ordered on the x axis according to physical mapping positions, with the most distal 17p13.3 probes
to the left and the most proximal 17p13.3 probes to the right. Below is a schematic of the deletion region. The deletion disrupts the PAFAH1B1/
LIS1 gene.
Figure 5 Oligonucleotide microarray characterization of an interstitial deletion at 6q14.1. The zoomed-in microarray plot shows a single-
copy loss of 43 oligonucleotide probes from the long arm of chromosome 6 at 6q14.1, approximately 2.9 Mb in size (chr6: 79,838,518-
82,730,466, based on UCSC 2006 hg 18 assembly). Probes are ordered on the x axis according to physical mapping positions, with the most
proximal 6q14.1 probes to the left and the most distal 6q14.1 probes to the right. Below is a schematic of the deletion region. Blue and gray
boxes represent genes in the deletion region.
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Page 10 of 14commonly used as justification for its proposed clinical
consequences; however, this association is not always
straightforward. High-resolution microarray analysis rou-
tinely detects abnormalities smaller than 500 kb that dis-
rupt clinically significant genes and have clear
phenotypic impact (Figure 4); conversely, numerous
examples of common copy-number variants have been
observed that are relatively large but lie in regions with
sparse gene content. In addition, although it is generally
assumed that de novo abnormalities are causative and
inherited abnormalities are not, this is not always the
case. There are a number of regions of the genome
where both inherited and de novo copy number altera-
tions have been identified, some of which result in mild
phenotypes that may be inherited from parents who have
a milder or subclinical, presentation. For example, dele-
tions of distinct regions of 1q21 have been associated
with both thrombocytopenia absent radius (TAR) syn-
drome and a variable phenotype including microcephaly/
macrocephaly, developmental delay, cardiac abnormal-
ities, and schizophrenia [29-31], but in many instances
aberrations of these regions are inherited from phenoty-
pically normal parents [32]. Another example is the
16p11.2 region associated with a range of cognitive,
developmental, and speech delays, behavioral issues, and
autism, deletions and duplications of which can be inher-
ited or de novo [33-36]. In regions such as these, copy
number changes may unmask recessive alleles or work in
conjunction with various genetic modifiers, perhaps even
other CNVs, to produce a clinical phenotype. Potentially,
non-paternity may also confound genotype-phenotype
correlation for copy number alterations in these complex
regions of the genome. These reasons underscore the
need for thorough databases of normal population var-
iants and clinically significant alterations complete with
genotype-phenotype correlations. Such databases expe-
dite the process of determining the potential significance
of copy-number alterations in a diagnostic setting; aid in
the elucidation of new microdeletion/duplication syn-
dromes and new regions of benign copy-number varia-
tion; and help reduce the burden of expensive, time-
consuming, and difficult follow-up necessitated by the
increased number of alterations of unclear clinical signifi-
cance detected by microarray analysis.
We [19] and others [37] have shown that mosaicism
can be detected at low frequencies of chromosomally
abnormal cells using BAC-based aCGH; however, the
ability of oligo platforms to reliably detect mosaic
abnormalities has not yet been well established. Our
current assessments demonstrate that aCGH using
Figure 6 BAC microarray characterization of a 9q33.1 deletion. The zoomed-in microarray plot shows a single-copy loss of three BAC clones
from the long arm of chromosome 9 at 9q33.1, approximately 262 kb in size (chr9: 119,452,279-119,714,054 based on UCSC 2006 hg 18
assembly). The nearest distal clone on chromosome 9 that is not deleted is RP11-977E8 and is approximately 4.0 Mb away from the deleted
region. The nearest proximal clone on chromosome 9 that is not deleted is RP11-999I23 and is approximately 4.4 Mb away from the deleted
region. Probes are ordered on the x axis according to physical mapping positions, with proximal 9q32 clones to the left and distal 9q33.2 clones
to the right. Below is a schematic of the deletion region. Vertical blue lines represent the minimum size of this alteration, which encompasses
one gene, TLR4.
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Page 11 of 14either BAC or oligo platforms can easily detect mosai-
cism of 30% or greater for a variety of alterations and
that levels as low as 10% can be detected with both plat-
forms under optimal conditions. In addition, our retro-
spective analysis showed that there is no significant
difference between the two types of platforms in the
number of mosaic abnormalities detected in a clinical
diagnostic setting (p = 0.7066). However, BAC-based
arrays may still have a greater ability to detect mosaic
abnormalities present at very low levels (less than 20%),
perhaps due to the routine use of dye-swap experiments
which can be cost-prohibitive with oligo arrays but pro-
mote the visual identification of mosaic abnormalities.
The sensitivity of the BAC array is demonstrated by the
detection in three cases of abnormalities in only 10% of
cells during the retrospective study, whereas the lowest
level of mosaicism detected by our oligo array was 21%
(Table 5). The ability of an aCGH platform to detect
mosaic abnormalities also depends largely on the effec-
tiveness of the software used to analyze the data, as
low-level mosaic alterations are difficult to identify using
only visual inspection (Figure 3). For this reason, it is
important to select analysis software which facilitates
the identification of mosaic alterations.
These data suggest high-resolution oligo-based aCGH
detects a higher proportion of clinically significant
abnormalities than BAC-based aCGH. Our results also
demonstrate the ability of microarray-based CGH to reli-
ably produce high-yield results in a clinical setting using
differing platforms, array designs, and analysis algorithms,
supporting the validity of array CGH as a first-tier diag-
nostic screening tool [38]. Finally, the prevalence of copy
number variants of unclear clinical significance detected
on both platforms underscores the need for the develop-
ment of readily accessible diagnostic tools in the form of
databases of documented chromosome abnormalities to
aid in the interpretation of microarray data.
Acknowledgements
We thank Aaron Theisen (Signature Genomic Laboratories, Spokane, WA) for
his careful edits of the paper and all of the laboratory staff at Signature
Genomics for conducting the aCGH and FISH experiments.
Authors’ contributions
NN wrote the manuscript; BST analyzed the molecular cytogenetics results;
BAB, BCB and LGS designed and coordinated the study. All authors have
read and approved the final manuscript.
Competing interests
NN, BST, BCB, BAB and LGS are employees of Signature Genomic
Laboratories, a subsidiary of PerkinElmer.
Received: 16 March 2010 Accepted: 29 June 2010
Published: 29 June 2010
References
1. Shaffer LG, Bejjani BA, Torchia B, Kirkpatrick S, Coppinger J, Ballif BC: The
identification of microdeletion syndromes and other chromosome
abnormalities: Cytogenetic methods of the past, new technologies for
the future. Am J Med Genet C Semin Med Genet 2007, 145C:335-345.
2. Shevell MI, Bejjani BA, Srour M, Rorem EA, Hall N, Shaffer LG: Array
comparative genomic hybridization in global developmental delay. Am J
Med Genet B Neuropsychiatr Genet 2008, 147B:1101-1108.
3. Ballif BC, Hornor SA, Jenkins E, Madan-Khetarpal S, Surti U, Jackson KE,
Asamoah A, Brock PL, Gowans GC, Conway RL, Graham JM Jr, Medne L,
Zackai EH, Shaikh TH, Geoghegan J, Selzer RR, Eis PS, Bejjani BA, Shaffer LG:
Figure 7 Oligonucleotide microarray characterization of an interstitial deletion at 4q25. The zoomed-in microarray plots shows a single-
copy loss of 15 oligonucleotide probes from the long arm of chromosome 4 at 4q25, approximately 159.6 kb in size (chr4: 108,834,399-
108,994,048, based on UCSC 2006 hg 18 assembly). Probes are ordered on the x axis according to physical mapping positions, with proximal
4q25 clones to the left and distal 4q25 clones to the right. Below is a schematic of the deletion region. The deletion disrupts the PAPSS1 and
SGMS2 genes, represented by blue boxes.
Neill et al. Molecular Cytogenetics 2010, 3:11
http://www.molecularcytogenetics.org/content/3/1/11
Page 12 of 14Discovery of a previously unrecognized microdeletion syndrome of
16p11.2-p12.2. Nat Genet 2007, 39:1071-1073.
4. Ballif BC, Theisen A, McDonald-McGinn DM, Zackai EH, Hersh JH, Bejjani BA,
Shaffer LG: Identification of a previously unrecognized microdeletion
syndrome of 16q11.2q12.2. Clin Genet 2008, 74:469-475.
5. Koolen DA, Vissers LE, Pfundt R, de Leeuw N, Knight SJ, Regan R, Kooy RF,
Reyniers E, Romano C, Fichera M, Schinzel A, Baumer A, Anderlid BM,
Schoumans J, Knoers NV, van Kessel AG, Sistermans EA, Veltman JA,
Brunner HG, de Vries BB: A new chromosome 17q21.31 microdeletion
syndrome associated with a common inversion polymorphism. Nat
Genet 2006, 38:999-1001.
6. Sharp AJ, Hansen S, Selzer RR, Cheng Z, Regan R, Hurst JA, Stewart H,
Price SM, Blair E, Hennekam RC, Fitzpatrick CA, Segraves R, Richmond TA,
Guiver C, Albertson DG, Pinkel D, Eis PS, Schwartz S, Knight SJ, Eichler EE:
Discovery of previously unidentified genomic disorders from the
duplication architecture of the human genome. Nat Genet 2006,
38:1038-1042.
7. Sharp AJ, Selzer RR, Veltman JA, Gimelli S, Gimelli G, Striano P, Coppola A,
Regan R, Price SM, Knoers NV, Eis PS, Brunner HG, Hennekam RC, Knight SJ,
de Vries BB, Zuffardi O, Eichler EE: Characterization of a recurrent 15q24
microdeletion syndrome. Hum Mol Genet 2007, 16:567-572.
8. Shaw-Smith C, Pittman AM, Willatt L, Martin H, Rickman L, Gribble S,
Curley R, Cumming S, Dunn C, Kalaitzopoulos D, Porter K, Prigmore E,
Krepischi-Santos AC, Varela MC, Koiffmann CP, Lees AJ, Rosenberg C,
Firth HV, de Silva R, Carter NP: Microdeletion encompassing MAPT at
chromosome 17q21.3 is associated with developmental delay and
learning disability. Nat Genet 2006, 38:1032-1037.
9. Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, de Vries BB,
Janssen IM, van der Vliet WA, Huys EH, de Jong PJ, Hamel BC,
Schoenmakers EF, Brunner HG, Veltman JA, van Kessel AG: Mutations in a
new member of the chromodomain gene family cause CHARGE
syndrome. Nat Genet 2004, 36:955-957.
10. Sharp AJ: Emerging themes and new challenges in defining the role of
structural variation in human disease. Hum Mutat 2009, 30:135-144.
11. Cytrynbaum CS, Smith AC, Rubin T, Weksberg R: Advances in overgrowth
syndromes: clinical classification to molecular delineation in Sotos
syndrome and Beckwith-Wiedemann syndrome. Curr Opin Pediatr 2005,
17:740-746.
12. Gropman AL, Elsea S, Duncan WC Jr, Smith AC: New developments in
Smith-Magenis syndrome (del 17p11.2). Curr Opin Neurol 2007,
20:125-134.
13. Ballif BC, Theisen A, Coppinger J, Gowans GC, Hersh JH, Madan-Khetarpal S,
Schmidt KR, Tervo R, Escobar LF, Friedrich CA, McDonald M, Campbell L,
Ming JE, Zackai EH, Bejjani BA, Shaffer LG: Expanding the clinical
phenotype of the 3q29 microdeletion syndrome and characterization of
the reciprocal microduplication. Mol Cytogenet 2008, 1:8.
14. Coppinger J, McDonald-McGinn D, Zackai E, Shane K, Atkin JF, Asamoah A,
Leland R, Weaver DD, Lansky-Shafer S, Schmidt K, Feldman H, Cohen W,
Phalin J, Powell B, Ballif BC, Theisen A, Geiger E, Haldeman-Englert C,
Shaikh TH, Saitta S, Bejjani BA, Shaffer LG: Identification of familial and de
novo microduplications of 22q11.21-q11.23 distal to the 22q11.21
microdeletion syndrome region. Hum Mol Genet 2009, 18:1377-1383.
15. Shaffer LG, Theisen A, Bejjani BA, Ballif BC, Aylsworth AS, Lim C,
McDonald M, Ellison JW, Kostiner D, Saitta S, Shaikh T: The discovery of
microdeletion syndromes in the post-genomic era: review of the
methodology and characterization of a new 1q41q42 microdeletion
syndrome. Genet Med 2007, 9:607-616.
16. Bejjani BA, Saleki R, Ballif BC, Rorem EA, Sundin K, Theisen A, Kashork CD,
Shaffer LG: Use of targeted array-based CGH for the clinical diagnosis of
chromosomal imbalance: Is less more? Am J Med Genet A 2005,
134:259-267.
17. Bejjani BA, Shaffer LG, Ballif BC: The use of microarray technology for
cytogenetics. Methods Mol Biol 2010, 632:125-139.
18. Traylor RN, Fan Z, Hudson B, Rosenfeld JA, Shaffer LG, Torchia BS, Ballif BC:
Microdeletion of 6q16.1 encompassing EPHA7 in a child with mild
neurological abnormalities and dysmorphic features: case report. Mol
Cytogenet 2009, 2:17.
19. Ballif BC, Rorem EA, Sundin K, Lincicum M, Gaskin S, Coppinger J,
Kashork CD, Shaffer LG, Bejjani BA: Detection of low-level mosaicism by
array CGH in routine diagnostic specimens. Am J Med Genet A 2006,
140:2757-2767.
20. Lo Nigro C, Chong CS, Smith AC, Dobyns WB, Carrozzo R, Ledbetter DH:
Point mutations and an intragenic deletion in LIS1, the lissencephaly
causative gene in isolated lissencephaly sequence and Miller-Dieker
syndrome. Hum Mol Genet 1997, 6:157-164.
21. Williams SN, Locke CJ, Braden AL, Caldwell KA, Caldwell GA: Epileptic-like
convulsions associated with LIS-1 in the cytoskeletal control of
neurotransmitter signaling in Caenorhabditis elegans. Hum Mol Genet
2004, 13:2043-2059.
22. Chuang JL, Wynn RM, Moss CC, Song JL, Li J, Awad N, Mandel H,
Chuang DT: Structural and biochemical basis for novel mutations in
homozygous Israeli maple syrup urine disease patients: a proposed
mechanism for the thiamin-responsive phenotype. J Biol Chem 2004,
279:17792-17800.
23. Edelmann L, Wasserstein MP, Kornreich R, Sansaricq C, Snyderman SE,
Diaz GA: Maple syrup urine disease: identification and carrier-frequency
determination of a novel founder mutation in the Ashkenazi Jewish
population. Am J Hum Genet 2001, 69:863-868.
24. Nobukuni Y, Mitsubuchi H, Akaboshi I, Indo Y, Endo F, Yoshioka A,
Matsuda I: Maple syrup urine disease. Complete defect of the E1 beta
subunit of the branched chain alpha-ketoacid dehydrogenase complex
due to a deletion of an 11-bp repeat sequence which encodes a
mitochondrial targeting leader peptide in a family with the disease.
J Clin Invest 1991, 87:1862-1866.
25. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D,
Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P,
Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/
10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
26. Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC: Identification
of a family of animal sphingomyelin synthases. EMBO J 2004, 23:33-44.
27. Xu ZH, Otterness DM, Freimuth RR, Carlini EJ, Wood TC, Mitchell S, Moon E,
Kim UJ, Xu JP, Siciliano MJ, Weinshilboum RM: Human 3’-
phosphoadenosine 5’-phosphosulfate synthetase 1 (PAPSS1) and
PAPSS2: gene cloning, characterization and chromosomal localization.
Biochem Biophys Res Commun 2000, 268:437-444.
28. Bailey JA, Kidd JM, Eichler EE: Human copy number polymorphic genes.
Cytogenet Genome Res 2008, 123:234-243.
29. Brunetti-Pierri N, Berg JS, Scaglia F, Belmont J, Bacino CA, Sahoo T,
Lalani SR, Graham B, Lee B, Shinawi M, Shen J, Kang SH, Pursley A, Lotze T,
Kennedy G, Lansky-Shafer S, Weaver C, Roeder ER, Grebe TA, Arnold GL,
Hutchison T, Reimschisel T, Amato S, Geragthy MT, Innis JW, Obersztyn E,
Nowakowska B, Rosengren SS, Bader PI, Grange DK, et al: Recurrent
reciprocal 1q21.1 deletions and duplications associated with
microcephaly or macrocephaly and developmental and behavioral
abnormalities. Nat Genet 2008, 40:1466-1471.
30. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S,
Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T,
Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A,
Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A,
Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M,
Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, Shianna KV, et al: Large
recurrent microdeletions associated with schizophrenia. Nature 2008,
455:232-236.
31. Klopocki E, Schulze H, Strauss G, Ott CE, Hall J, Trotier F, Fleischhauer S,
Greenhalgh L, Newbury-Ecob RA, Neumann LM, Habenicht R, Konig R,
Seemanova E, Megarbane A, Ropers HH, Ullmann R, Horn D, Mundlos S:
Complex inheritance pattern resembling autosomal recessive
inheritance involving a microdeletion in thrombocytopenia-absent
radius syndrome. Am J Hum Genet 2007, 80:232-240.
32. Mefford HC, Sharp AJ, Baker C, Itsara A, Jiang Z, Buysse K, Huang S,
Maloney VK, Crolla JA, Baralle D, Collins A, Mercer C, Norga K, de Ravel T,
Devriendt K, Bongers EM, de Leeuw N, Reardon W, Gimelli S, Bena F,
Hennekam RC, Male A, Gaunt L, Clayton-Smith J, Simonic I, Park SM,
Mehta SG, Nik-Zainal S, Woods CG, Firth HV, et al: Recurrent
rearrangements of chromosome 1q21.1 and variable pediatric
phenotypes. N Engl J Med 2008, 359:1685-1699.
33. Kumar RA, KaraMohamed S, Sudi J, Conrad DF, Brune C, Badner JA,
Gilliam TC, Nowak NJ, Cook EH Jr, Dobyns WB, Christian SL: Recurrent
16p11.2 microdeletions in autism. Hum Mol Genet 2008, 17:628-638.
34. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M,
Moessner R, Pinto D, Ren Y, Thiruvahindrapduram B, Fiebig A, Schreiber S,
Friedman J, Ketelaars CE, Vos YJ, Ficicioglu C, Kirkpatrick S, Nicolson R,
Neill et al. Molecular Cytogenetics 2010, 3:11
http://www.molecularcytogenetics.org/content/3/1/11
Page 13 of 14Sloman L, Summers A, Gibbons CA, Teebi A, Chitayat D, Weksberg R,
Thompson A, Vardy C, Crosbie V, Luscombe S, Baatjes R, et al: Structural
variation of chromosomes in autism spectrum disorder. Am J Hum Genet
2008, 82:477-488.
35. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemundsen E,
Stefansson H, Ferreira MA, Green T, Platt OS, Ruderfer DM, Walsh CA,
Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, Santangelo SL, Gusella JF,
Sklar P, Wu BL, Daly MJ: Association between microdeletion and
microduplication at 16p11.2 and autism. N Engl J Med 2008, 358:667-675.
36. Rosenfeld JA, Coppinger J, Bejjani BA, Girirajan S, Eichler EE, Shaffer LG,
Ballif BC: Speech Delays and Behavioral Problems are the Predominant
Features in Individuals with Developmental Delays and 16p11.2
Microdeletions and Microduplications. J Neurodev Disord 2009, 0:1-13.
37. Cheung SW, Shaw CA, Scott DA, Patel A, Sahoo T, Bacino CA, Pursley A, Li J,
Erickson R, Gropman AL, Miller DT, Seashore MR, Summers AM,
Stankiewicz P, Chinault AC, Lupski JR, Beaudet AL, Sutton VR, et al:
Microarray-based CGH detects chromosomal mosaicism not revealed by
conventional cytogenetics. Am J Med Genet A 2007, 143:1679-1686.
38. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP,
Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L,
Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID,
Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB,
Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ,
Watson MS, et al: Consensus statement: chromosomal microarray is a
first-tier clinical diagnostic test for individuals with developmental
disabilities or congenital anomalies. Am J Hum Genet 86:749-764.
doi:10.1186/1755-8166-3-11
Cite this article as: Neill et al.: Comparative analysis of copy number
detection by whole-genome BAC and oligonucleotide array CGH.
Molecular Cytogenetics 2010 3:11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Neill et al. Molecular Cytogenetics 2010, 3:11
http://www.molecularcytogenetics.org/content/3/1/11
Page 14 of 14